立复欣与利福平治疗渗出性结核性胸膜炎的临床观察

目的比较立复欣与利福平在治疗结核性渗出性胸膜炎中的临床效果和副作用. 方法选择确诊的结核性渗出性胸膜炎80例,随机分为立复欣研究组与利福平对照组进行回顾性分析,立复欣研究组40例,利福平对照组40例. 结果立复欣研究组结核性渗出性胸膜炎痊愈62.5%,好转35%,无效2.5%,利福平对照组结核性渗出性胸膜炎痊愈30%,好转50%,无效20%.两组总有效率分别是97.5%和80%,两组比较差异有显著性(P<0.05),立复欣在肝功能、血象影响方面与对照组差异无显著性.结论应用立复欣方案在治疗结核性渗出性胸膜炎中有较好的临床价值,经济条件好的地区或住院患者可考虑应用.

Comparison of clinical effects and side effects of using Lifuxin and RFP in the treatment of the tuberculous pleurisy

Objective To compare the clinical effects and the side effects of using Lifuxin(Rifamycin) in vein and orally taking RFP in treating the tuberculous pleurisy, while they were treated with the same other anti-tuberculosis drugs (such as INH , PZA , levofloxacinhy drochloride). Methods 80 tuberculous pleurisy cases were randomly divided into two groups: one group (n=40) was treated with Lifuxin(Rifamycin), whereas the other group (n=40) was treated with RFP, while the both groups were treated with the same other anti-tuberculosis drugs. Results For the Lifuxin(Rifamycin) and RFP groups, the rates of recover were 62.5% and 30% respectively; the rates of improve ment were 35% and 50% respectively; the rates of inefficiency were 2.5% and 20% respectively. Again for the two groups, the rates of the pleural complete effusion absorption within 2 weeks were 57.5% and 25% respectively; the rates of the pleural effusion decrease within 1 month were 32.5% and 40% respectively; the rates of no decrease over 1 month were 32.6% and 35% respectively. The overall efficiencies of the two groups were 97.5% and 80% respectively. The overall comparison between the two groups showed a significant difference(P<0.05). However, the two groups were not significantly different in terms of measures of liver functions and blood Rt. Conclusion The use of Lifuxin(Rifamycin) has favorable clinical prospect in the treatment of tuberculous pleurisy; it can be suggested in rich areas.